Health · Pharma & Biotech · 6 hrs ago

FDA grants accelerated approval to GSK lung cancer drug Nelkarmi

FDA grants accelerated approval to GSK lung cancer drug Nelkarmi

The FDA granted US accelerated approval to GSK’s oral lung cancer drug neladalkib, marketed as Nelkarmi.

The drug is for lung cancer.

The approval makes it the second lung cancer drug approved from GSK’s $10.6bn deal to buy Nuvalent.

The deal included two key drug assets, according to the available details.

The approval matters because it gives GSK another lung cancer drug cleared for use in the US.

The available details do not say what happens next.

3 sources

Related

What people are saying

Endpoints NewsNot stated
GSK has secured a US accelerated approval for its oral lung cancer drug neladalkib
via Endpoints News